A schematic summary of the proposed hypothesis illustrates how Tnfsf9 treatment enhances rIL-12 therapy by promoting interactions among distinct immune cell populations, stimulatory ligands, and receptors at the tumor site (Figure 8). This evidence concerns the gene TNFSF9 and neoplasm.